TRIM21 and synovial sarcoma: The findings that autoantibodies target the entire Ro52 molecule, including the N-terminal ubiquitin ligase and C-terminal immunoglobulin-binding region, link the process of Ro52 intracellular immunoglobulin-coated pathogen targeting to the proteosome with the protein’s autoantigenicity in SS and other rheumatological diseases.